Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Ederra Bella Plastic Surgery and Medical Spa Awarded 2022 Top Patient Rated Johns Creek Plastic Surgeon by Find Local Doctors


News Image

“It is such an honor to be recognized as a 2022 Top Patient Rated Plastic Surgeon. I am truly passionate about helping patients look and feel their best,” says Dr. Myla Bennett-Powell.

Ederra Bella Plastic Surgery and Medical Spa is a full-service beauty center serving the Johns Creek and North Atlanta area. Dr. Myla Bennett-Powell’s exceptional reviews and five-star ratings have helped earn this distinguished award from Find Local Doctors. Find Local Doctors is a user-friendly online directory, that helps consumers connect with skilled physicians in their area who are well-known for their expertise. Dr. Myla Bennett-Powell and her team at Ederra Bella Plastic Surgery and Medical Spa help enhance patients’ natural beauty with a variety of surgical and non-surgical procedures and treatments. At the state-of-the-art clinic, patients enjoy a luxurious setting for cosmetic surgical, non-surgical and medical spa services, including facial rejuvenation, rhinoplasty, body sculpting, breast surgery, intimate plastic surgery, facelifts, dermal fillers and injectables, anti-aging treatments and more. Dr. Myla Bennett-Powell uses the latest cutting-edge techniques and treatments, and her training, experience, and skill generate superior outcomes in both surgical and non-surgical procedures. This talented doctor also created her own medical-grade skincare line, Ederra Bella Skin. The team at Ederra Bella Plastic Surgery and Medical Spa offers a compassionate approach and creates stunning, natural-looking results, with the goal of providing each patient with a truly individualized treatment plan that reflects aesthetic goals. When visiting Ederra Bella, it will be a unique experience in a faith-filled atmosphere.

“It is such an honor to be recognized as a 2022 Top Patient Rated Plastic Surgeon. I am truly passionate about helping patients look and feel their best,” says Dr. Myla BennettPowell.

More about Myla Bennett-Powell, M.D.

Dr. Myla Bennett-Powell is a well-respected, board-certified plastic surgeon and skin care expert. She earned her medical degree from the Ohio State University of Medicine and completed her plastic and reconstructive surgery and general surgery residencies there as well. She then continued her training at the university with admission to the fellowship program. With several years of experience in the industry, Dr. Myla Bennett-Powell uses her expertise to perform plastic surgery procedures and other treatments with the goal of enhancing patients’ natural beauty.

For more information on services available at Ederra Bella Plastic Surgery and Medical Spa, please call (678)-325-0006 or visit http://www.ederrabella.com.

Share article on social media or email:

CTL Amedica gains FDA clearance for MONDRIAN™ ALIF Cage System with Supplementary Fixation Plate


The MONDRIAN™ ALIF Cage System with Supplementary Fixation Plate features TiCro™ surface technology, which significantly increases endplate contact surface area and enhances interlocking properties.

This innovative product is designed to provide exceptional anterior column stabilization and supplemental fixation, while providing operative flexibility and accommodating a wider range of patient anatomies.

CTL Amedica Corporation has received official 510k clearance from the U.S. Food and Drug Administration (FDA) to market its MONDRIAN™ Anterior Lumbar Interbody Fusion (ALIF) Cage System with Supplementary Fixation Plate. The MONDRIAN™ ALIF Cage System with Supplementary Fixation Plate, designated K213641/S003, is an integrated plate-and-cage construct, that can be manufactured in PEEK, titanium and a hybrid titanium-plated PEEK. The system, a standalone extension to the already robust MONDRIAN™ offering, features CTL Amedica’s proprietary TiCro™ surface technology, which significantly increases endplate contact surface area and enhances interlocking properties.

“This innovative product is designed to provide exceptional anterior column stabilization and supplemental fixation, while providing operative flexibility and accommodating a wider range of patient anatomies,” said Daniel Chon, CEO of CTL Amedica. “We’re excited about the FDA approval and look forward to introducing the MONDRIAN™ ALIF Cage System with Supplementary Fixation Plate to the industry this week.”

The MONDRIAN™ ALIF Cage System with Supplementary Fixation Plate features an efficient screw-locking mechanism, a supplementary screw-blocking plate for additional reinforcement, a significant lateral aperture for improved imaging, and a large central chamber that maximizes graft volume. The system introduces hyperlordotic offerings to the CTL Amedica portfolio and features a smooth and tapered leading-edge for easy insertion and multiple screw plate configurations to better accommodate patient anatomy and surgical preference.

CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. In addition, it is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates an enhanced osteogenic response for enhanced fusion, promotes unique anti-bacterial properties and provides comprehensive imaging across all modalities. For more information, visit https://www.ctlamedica.com/.

Share article on social media or email:

Liine Raises $3M To Scale AI-Powered Patient Acquisition Platform


“We’re excited to partner with Liine to scale the team and continue building its industry-leading platform,” said Ramsay Battin, Partner at Eastside Partners.

Liine, the leading AI-powered call recording and automation platform for specialty healthcare and dental practices, announced it has secured approximately $3.0M in funding led by Eastside Partners. This latest financing will allow Liine to accelerate product development and go-to-market initiatives as it meets the rapidly growing demand for better, more comprehensive patient acquisition tools.

“We are thrilled to work with Eastside Partners as we enter our next phase of growth,” said Brad Blaser, CEO and co-founder of Liine. “Although we weren’t actively pursuing additional capital, the opportunity to partner with a premier healthcare investor like Eastside and double down on our mission to simplify patient acquisition was too hard to pass up.”

“Growth-oriented practices are increasingly adopting lead management software but often find traditional CRMs like Salesforce don’t meet the unique needs of the healthcare industry,” said CRO and co-founder Charlie Wiin. “Liine, which was purpose built for provider offices and call centers, has capitalized on this trend and now serves some of the top group practices, MSOs (management services organizations) and DSOs (dental support organizations) in the country.”

By automatically analyzing 100% of new patient interactions (phone calls, web forms, chat bots, online bookings, etc.), Liine provides full visibility into a practice’s patient acquisition efforts. With absolutely no manual data entry required from staff, the platform captures key insights related to new patient volumes, appointment conversion rates, staff performance, marketing efficiency, and much more. Additionally, Liine automates the follow up process for online form submissions and other asynchronous patient inquiries. With Liine’s FormFlow technology, the average practice improves their lead-to-appointment conversion rate by more than 30%.

“We’re excited to partner with Liine to scale the team and continue building its industry-leading platform,” said Ramsay Battin, Partner at Eastside Partners. “We know that providers are laser-focused on maximizing the return of their marketing investments. Liine’s team has built an extremely impressive solution that meets this need while ‘threading the needle’ between ease of use and immediate financial impact.”

As part of this transaction, Ramsay Battin and Arun Mohan, MD (co-founder of Radix Health and President of Relatient) will be joining the Company’s board of directors.

About Liine

Headquartered in Raleigh, NC, Liine was founded in 2016 to help simplify and improve lead management for specialty healthcare and dental practices. Leveraging artificial intelligence and natural language processing, Liine automates the data and workflow to maximize new patient growth. Learn more at http://www.liine.com.

About Eastside Partners

Eastside Partners is a growth-equity firm that backs management teams who are building exceptional products and services. Since 2005, the firm has invested more than $250 million, focusing on B2B SaaS, Healthcare and Tech-Enabled Services companies. Eastside’s investment strategy is focused on companies whose culture always puts the customer first.

Media Contact:

Ken Pittman

VP Marketing

Liine

kpittman@liine.com

336-448-6390

Share article on social media or email:

U.S. Oral Surgery Management Names Erik Pahl General Counsel, Chief Compliance Officer


Pahl is a business-oriented executive with more than 20 years of in-house healthcare experience.

We have the largest and fastest growing network of oral and maxillofacial surgeons nationwide, and we want to continue building on that,

In response to its continued growth, U.S. Oral Surgery Management(USOSM) – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – has hired Erik Pahl as general counsel and chief compliance officer. In this role, Pahl will be responsible for all legal and compliance matters that concern USOSM and its partner practices.

“We have the largest and fastest growing network of oral and maxillofacial surgeons nationwide, and we want to continue building on that,” said Richard Hall, USOSM president, and CEO. “Erik’s extensive transactional background is going to help catalyze our next stage of growth. In addition, while we already have a great compliance program in place, Erik will continue to build on our foundation by leading and overseeing the program. Erik is a highly trusted business advisor, who will make an excellent addition to our team.”

Pahl is a business-oriented executive with more than 20 years of in-house healthcare experience. He has extensive expertise in advising a wide variety of boards, shareholders, providers, and management teams.

“I am honored and thrilled to begin this new role. This is a transformational time in healthcare and USOSM will continue to be a leader in our industry. I am looking forward to helping guide an organization that is dedicated to excellent patient care and superb customer service,” noted Pahl.

Most recently, Pahl was the general counsel and chief compliance officer for Summus Healthcare and Prime DataQ Health. While there, Pahl oversaw all acquisitions and divestitures and maintained a robust corporate compliance program. Prior to that, Pahl served as general counsel for LifeCare Health Partners, Intrepid USA, and Snelling Staffing. He also served as division counsel for Kindred Healthcare’s home health and hospice division.

Pahl began his legal career as a judge advocate with the U.S. Air Force, where he served on active duty, and later with the Reserves and Air National Guard. He retired from the Air Force at the rank of Lieutenant Colonel.

“I am truly humbled by this opportunity and the trust that Rick Hall and the rest of the senior leadership team have placed in me,” added Pahl. “I look forward to using my experience in M&A, compliance, healthcare operations, and regulatory matters to help take USOSM to the next level.”

Pahl earned his bachelor’s degree in finance from Miami University in Oxford, Ohio. He earned his JD from DePaul University College of Law in Chicago, Illinois.

Headquartered in Irving, Texas, USOSM has partner practices spanning 21 states. They include Texas, Colorado, Georgia, Tennessee, Minnesota, Alabama, Oklahoma, Louisiana, South Carolina, Mississippi, Florida, Indiana, Kentucky, Arizona, California, Oregon, Virginia, Washington, Massachusetts, Michigan, and Illinois. A shared services organization, USOSM collaborates with premier oral and maxillofacial surgeons to offer a partnership solution for continued and accelerated practice success. USOSM provides operational, marketing, and administrative support services reinvest resources, and apply best practices to improve clinical and financial performance and produce steadier, more profitable growth for all. For more information, visit https://www.usosm.com/.

Share article on social media or email:

Protect Environmental Completes Acquisition of Reliant Radon Solutions


Graphic | Protect Environmental Acquires Reliant Radon

Protect Environmental Acquires Reliant Radon

“I’m honored to join the Protect Environmental family to continue this commitment in the communities we serve,” Terry Kerwin, owner of Reliant Radon Solutions, said of the acquisition.

Louisville-based Protect Environmental, a national leader in the environmental consulting and construction industry, with a focus on radon and chemical vapor intrusion management, today announced its acquisition of Reliant Radon Solutions. After acquiring Denver-based ACE Radon earlier this year, the company is continuing to expand its capacity to serve Colorado and the western United States.

Founded in 2003, Reliant Radon Solutions has focused on building trust with residential and commercial customers seeking radon testing, mitigation, and monitoring in Colorado and throughout the western region of the country. Terry Kerwin, owner of Reliant Radon Solutions, says of the acquisition, “over the years we’ve been committed to our community through providing education and quality services, and I’m honored to join the Protect Environmental family to continue this commitment in the communities we serve.”

Coupled with the acquisition of ACE Radon, the expanded operation is the largest, most experienced soil gas contractor in the state of Colorado. “Reliant Radon Solutions has always been a strong competitor in the market, which is why we are excited to join forces to amplify our ability to serve the Denver area and beyond,” said Jeff Goard, Director of Colorado Operations.

As part of the acquisition, Kerwin will transition to a national role within the company, leading its market development team and supporting its national accounts team. “We are excited to welcome Reliant Radon Solutions to Protect Environmental’s growing family, particularly given the alignment with our core values and vision,” said Kyle Hoylman, CEO of Protect Environmental. “I look forward to working with Terry on the national level to assist our clients with building and maintaining healthy, safe, and sustainable indoor environments in the communities where we live, work, and learn.”

About Protect Environmental

Protect Environmental is a national leader in the environmental consulting and construction industry, focusing on radon and chemical vapor intrusion management. With a proven track record spanning 18 years and more than 200,000 completed projects in all 50 U.S. states and 2 U.S. territories, the company provides expert service from its trusted professionals to provide peace of mind protection to property owners seeking to build and maintain healthy, safe, and sustainable indoor environments. For more information, call 502-410-5000 or click on https://www.protectenvironmental.com.

-xxxx-

Share article on social media or email:

Clear Labs to Present at IDWeek on Role of Whole Genome Sequencing in Hospitals


News Image

Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is announcing plans to attend key events in October.

Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is announcing plans to attend key events in October that are focused on microbiology, pathogen surveillance, and outbreak management, including sponsoring and presenting at this year’s IDWeek in Washington, DC. In addition, Clear Labs is sponsoring a Learning Lounge at the event, which is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

The company is also attending important regional events on the West Coast, including the California Association of Public Health Lab Directors (CAPHLD) Annual Institute and the Southern California branch of the American Society for Microbiology’s (SCASM) Annual Meeting.

IDWeek

  • -WHAT: Clear Labs is a sponsoring Learning Lab and presenting on “Is Whole Genome Sequencing Ready for Prime Time? Removing the hurdles to adoption of WGS in the hospital setting for infection control and prevention”
  • -WHEN: Friday, October 21, 2022, from 11:15 a.m. to 12:00 p.m.
  • -WHERE: Walter E. Washington Convention Center; Hall A, Learning Lounge 3, in Washington, D.C.
  • -WHO: Clear Labs’ Associate Director of Bioinformatics, Adam Allred, Ph.D and Assistant Director of the Clinical Microbiology Laboratory, Hospital of the University of Pennsylvania, Kyle Rodino, Ph.D.

CAPHLD Annual Institute

  • -WHAT: Clear Labs is attending the event focused on improving and protecting public health through the promotion and advancement of public health laboratory practice.
  • -WHEN: October 17-19, 2022
  • -WHERE: Embassy Suites in Walnut Creek, CA

SCASM Annual Meeting

  • -WHAT: Clear Labs is attending the meeting focused on promoting microbiology education and research in Southern California – spanning areas from clinical, public health, environmental, basic research, education, industrial, food safety, veterinary, and more.
  • -WHEN: October 20-22, 2022
  • -WHERE: Hyatt Regency La Jolla at Aventine in La Jolla, CA

Clear Labs continues to see momentum for its Clear Dx™ platform that determines the nature of pathogen transmission, differentiates strains, and monitors mutations and new variants; it is currently being used by more than half of the public health labs in the United States. For more information about Clear Labs and upcoming events, visit https://www.clearlabs.com/newsroom/.

About Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics, and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy for the detection and surveillance of infectious diseases. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Share article on social media or email:

HearingLife and Alzheimer’s Association Announce Partnership to Fight Against Dementia


News Image

“Research shows that prescription hearing aids can help in maintaining a social lifestyle, which contributes to a healthy brain and possibly lowers the risk of developing dementia.”

HearingLife, a leader in delivering life-changing, personalized hearing care in 42 states, today announced a corporate partnership with the Alzheimer’s Association. HearingLife will donate $100,000 to the Alzheimer’s Association to help advance research and fund the Association’s care and support programs.

“We are committed to supporting this important cause by joining forces with the Alzheimer’s Association to support their mission and to educate the community about the cognitive risks associated with hearing impairment and loss,” said Dean Pappous, President of HearingLife. “Research shows that prescription hearing aids can help in maintaining a social lifestyle, which contributes to a healthy brain and possibly lowers the risk of developing dementia. Through this partnership, we’re eager to support the Alzheimer’s Association’s mission to drive risk reduction, accelerate global research and promote early detection.”

According to the “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission,” untreated hearing loss can lead to lowered mental stimulation, as your brain is not working to identify different sounds and nuances. The portion of your brain responsible for transmitting sound becomes weaker, making memory loss and cognitive decline more likely. HearingLife and the Alzheimer’s Association are working together to bring this life-altering medical condition into focus. According to the World Health Organization, 1 in 4 individuals are expected to have hearing loss by 2050. HearingLife will also create awareness in their hearing care centers and through media efforts, while offering its customers the opportunity to make personal contributions to the Alzheimer’s Association cause during the duration of the campaign. Visit hearinglife.com/alz to learn more.

“The Alzheimer’s Association is grateful for the commitment and enthusiasm HearingLife brings to supporting our mission of reducing the risk of Alzheimer’s and all other dementia,” said Liz Adams, Chief Development Officer, Alzheimer’s Association. “There is emerging evidence showing that hearing loss may contribute to a person’s risk of cognitive decline and possibly dementia. This funding will enable researchers to better understand contributors to cognitive decline.”

About HearingLife

HearingLife is a national hearing care company and part of the Demant Group, a global leader in hearing healthcare built on a heritage of care, health, and innovation since 1904. HearingLife operates nearly 700 hearing care centers across 42 states. We follow a scientific, results-oriented approach to hearing healthcare that is provided by highly skilled and caring professionals. Our vision is to help more people hear better through life-changing hearing health delivered by the best personalized care. To learn more, visit: https://www.hearinglife.com.

About the Alzheimer’s Association®

The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. For more information, visit alz.org or call the 24/7 Helpline at 800.272.3900.

PRESS CONTACT:

Kaplow Communications

(646) 747-3551

hearinglife@kaplow.com

Share article on social media or email:

BONESUPPORT’s FDA Authorized CERAMENT® G to be featured at Orthopedic Trauma Association Annual Meeting (OTA)


News Image

During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market authorization from the US Food and Drug Administration (FDA).

This week, BONESUPPORT, an emerging leader in orthobiologics, is attending the Orthopedic Trauma Association (OTA) annual meeting in Tampa, Florida. OTA is bringing together more than 400 accomplished orthopedic trauma surgeon presenters/moderators/authors who are sharing their expertise and experience, including delivering cutting-edge research findings and unique multi-national treatment perspectives. During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market authorization from the US Food and Drug Administration (FDA).

Conducted at Oxford University Hospitals, the significant study followed 100 consecutive patients and found that with the use of CERAMENT G, 94% were infection free at a mean follow-up of six years. It also showed a 3% fracture rate with no further pathologic fractures beyond the first year after surgery.

“This study is completely unique, as it is the first time a comprehensive analysis was completed with such a strict protocol – and the results are powerful,” said Emil Billbaeck, CEO of BONESUPPORT. “This study showcases the efficacy of our technology for reducing infection and provides another solid proof point of the significant difference our bone remodeling capabilities make for patients and clinicians alike.”

No other bone graft company has invested in such sophisticated research as BONESUPPORT

BONESUPPORT’s OTA Schedule

Friday, October 14, 2022:

  • -What: Breakfast Symposium featuring Prof. Martin McNally, who will present on the challenges of fracture related infections and share the Oxford experience, including mid-long term results with CERAMENT® G – the first & only FDA-authorized injectable antibiotic-eluting bone graft substitute by BONESUPPORT™
  • -When: 7:00 – 7:50 a.m. ET
  • -Where: Room 118

Friday, October 14:

  • -What: Annual Foot and Ankle meeting: “How Do Treatment Methods Affect Outcome of Surgery for Fracture-Related Infection?” featuring presenting author: Martin McNally, MD, MBCHB (Bone Infection Unit)
  • -When: 4:31 – 4:37 p.m. ET
  • -Where: West Exhibit Hall

For more information about the company and its groundbreaking approach, visit http://www.bonesupport.com.

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to demonstrate further the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Share article on social media or email:

IMMUSE™ Interactive Masterclass Explores Immune System Balance To Build Lifelong Resilience


News Image

Kyowa Hakko USA, leading international health ingredient manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products, is excited to announce an interactive masterclass on Wednesday, October 19th at 2:00 pm EDT to discuss, and educate, on the innovative approach of balancing the immune system instead of boosting it to optimize health and build lifelong resilience.

World-class expert Dr. Colin Hill, in his role of board member and former president of ISAPP (International Scientific Association for Probiotics and Prebiotics), will share his unique insights about postbiotics and the opportunities they hold for human health. Dr. Heather Moday, MD, author of “The Immunotype Breakthrough,” will guide the discussion on balancing the immune system by using personal immunotypes.

The “Know Your Personal Immunotype” Masterclass features IMMUSE™, a postbiotic that delivers an innovative breakthrough approach for more comprehensive immune support*. It is also aligned with the Kyowa Hakko’s efforts to support the education of complex scientific topics for its customers and the public in general.

After diving in on this insightful discussion, hosted by wellness coach Jamie Hess, a lively Q&A session follows with Dr. Moday and Danielle Citrolo, PharmD. Vice President, Scientific and Regulatory Affairs at Kyowa Hakko.

To register online for the “Know Your Personal Immunotype” masterclass, visit: https://bit.ly/DrMVW2022

For media inquiries, please get in touch with Giselle Chollett at giselle@adinnyc.com or 917.386.7116

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About IMMUSE™:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by over 29 published studies, including 14 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells) *. The pDC, a rare type of immune cell, functions as the key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About Dr. Hill

Dr. Hill has a Ph.D in molecular microbiology and is Professor of Microbial Food Safety in the School of Microbiology at University College Cork, Ireland. He has been an SFI Principal Investigator since 2002. He is also a Principal Investigator in APC Microbiome Ireland. His main interests are in mining the microbiome for novel therapies, including probiotics, postbiotics, bacteriocins and bacteriophage. He has published more than 650 peer-reviewed papers and holds more than 25 patents in this area (ISI H factor of 93, Google H factor of 125). In 2005 Prof. Hill was awarded a D.Sc. by the National University of Ireland in recognition of his contributions to research. In 2009 he was elected to the Royal Irish Academy, the highest honor for an Irish academic. In 2010 he was elected to the American Academy of Microbiology and together with his colleagues Prof. Gerald Fitzgerald, Prof. Paul Ross and Dr Catherine Stanton he was awarded the Metchnikoff Prize in Microbiology. He served as President of ISAPP (International Scientific Association for Prebiotics and Probiotics) from 2012 to 2015.

About Dr. Heather Moday:

Dr. Moday is the owner of the Moday Center for Functional Medicine and Integrative Medicine, which offers comprehensive medical and nutritional programs for adults that focus on preventing and treating chronic diseases to achieve optimal wellness. She has a special interest in immune system dysfunction, including autoimmunity, allergy, the stress-immune connection, Chronic GI dysfunction, cognitive decline, and mood disorders. Dr. Moday received her MD from Tulane Medical School in New Orleans and completed a residency in Internal Medicine and a fellowship in Allergy and Immunology at Montefiore/ Albert Einstein Medical center in New York City. After years of working as an allergist in private practice, she completed a fellowship in Integrative Medicine at the Arizona Center of Integrative Medicine. She is also a certified practitioner through the Institute for Functional Medicine.

Share article on social media or email:

Dr. Samuel Pang of Boston IVF Receives American Society for Reproductive Medicine 2022 Arnold P. Gold Foundation Humanism in Medicine Award for Practicing Physicians


Fertility Doctor, Boston IVF

Samuel C. Pang, MD

“I have two children conceived through IVF, so I have experienced both sides of the IVF process, as a physician and as a patient. I empathize with my IVF patients and am very grateful to have been able to build my family through the same services I provide.” – Samuel C. Pang, MD

Boston IVF, a worldwide leader of infertility treatment and family building, is honored to announce that Samuel C. Pang, M.D. has been selected by the American Society of Reproductive Medicine (ASRM) as the recipient of its 2022 Arnold P. Gold Foundation Humanism in Medicine Award for Practicing Physicians. This award is to be presented to Dr. Pang on October 23, 2022 at the 78th annual ASRM Scientific Congress and Expo in Anaheim, CA.

The ASRM is a worldwide leader for multidisciplinary education and standard of care in reproductive medicine, with the goal of ensuring accessible, ethical, and quality care for all people.

Dr. Pang, a board-certified reproductive endocrinologist, is Co-Director of Third-Party Reproduction at Boston IVF. He treats individuals and couples at the network’s fertility centers in Lexington, MA and Worcester, MA, where he is a valuable infertility treatment and family building resource for all Massachusetts residents. This includes numerous surrounding local communities, such as Milford, MA.

His exceptional reputation, commitment to clinical excellence, and meticulous attention to detail in patient care make Dr. Pang the prototypical honoree of the Arnold P. Gold Foundation Humanism in Medicine Award for Practicing Physicians, which uniquely recognizes a physician’s respectful and compassionate communication with patients, thereby engendering their trust and confidence.

“I have two children conceived through IVF, so I have experienced both sides of the IVF process, as a physician and as a patient,” said Samuel Pang, M.D., who is a resident of Lincoln, MA. “I can empathize with my patients who are undergoing the IVF process. I’m very grateful to have been able to build my family through the same services I provide to my patients and am deeply honored to be recognized by the ASRM with this award.”

Along with this ASRM recognition, Dr. Pang has been the recipient of eleven consecutive Top Fertility Doctor awards by Boston Magazine (2012-2022).

“Third-Party Reproduction” refers to the use of eggs, sperm or embryos that have been donated by a third party (donor), or use of a gestational surrogate. The donor eggs, donor sperm, donor embryos or gestational surrogate are used in assisted reproductive technology (ART) procedures such as IVF to enable an infertile individual or couple to become parents.

Third-Party Reproduction is commonly utilized by members of the LGBTQIA+ community.

Dr. Pang is a pioneer in providing reproductive care to LGBTQIA+ patients. In 1998, he was among the earliest physicians in the United States and the world to apply assisted reproductive technologies (ART) to gay men who sought parenthood via donor eggs and gestational surrogacy.

In 2007, he began providing IVF services to lesbian couples without infertility, coining the term “reciprocal IVF” for one person providing oocytes and the other gestating. In 2012, he began treating transgender people for fertility preservation and reciprocal IVF, as well as transgender men who choose to gestate themselves.

Dr. Pang holds a deep commitment to advocating for the rights of all people and an individual’s reproductive freedom. He has been a passionate philanthropic supporter of multiple LGBTQIA+ organizations which advocate for equality, among them GLBTA Legal Advocates & Defenders (GLAD), Human Rights Campaign (HRC), and Greater Boston PFLAG.

“Dr. Pang is a passionate advocate for all people who wish to build a family,” said David Stern, CEO of the Boston IVF fertility network. ​”On behalf of everyone at Boston IVF, we congratulate him for ​being selected to receive such a meaningful and well-deserved, national award. Dr. Pang’s superior level of reproductive care and longstanding philanthropic efforts continue to make a difference in the lives ​of his patients and ​the vital organizations he supports.”

To learn more about Dr. Pang, receive fertility advice, or to schedule a consultation, visit http://www.bostonivf.com/

Follow Boston IVF on Instagram

Follow Boston IVF on Facebook

Follow Boston IVF on LinkedIn

Subscribe to Boston IVF on YouTube

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 125,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email: